Table 2. Statistical analysis of immunogenicity following immunotherapy.
.
| Cohort | Peptide | Wk6 | Wk10 | Wk18 |
|---|---|---|---|---|
| TV Ad35+ vs NC-T4 | Ag85A CD4 | * | * | |
| Ag85A CD8 | **** | **** | ||
| Ag85B CD8 | **** | * | ||
| Ag85A pool | **** | **** | ||
| Ag85B pool | **** | **** | ||
| TB10.4 pool | **** | ** | ||
| TV Ad26+ vs TV Ad26- | Ag85A CD4 | * | ||
| Ag85A CD8 | *** | |||
| Ag85B CD8 | * | |||
| Ag85A pool | ** | |||
| Ag85B pool | *** | |||
| TB10.4 pool | ** | |||
| TV Ad35+ vs NC-IU | Ag85A CD4 | NS | NS | |
| Ag85A CD8 | NS | NS | ||
| Ag85B CD8 | NS | NS | ||
| Ag85A pool | * | NS | ||
| Ag85B pool | NS | NS | ||
| TB10.4 pool | NS | NS |
Results of statistical analysis two weeks following immunotherapy with Ad35-TBS and Ad26-TBS, for all peptides tested in the ELISpot assay.
* p-value <0.05
** p-value <0.01
***p-value <0.001
****p-value <0.0001
One-way ANOVA with Tukey’s multiple comparisons test and t-test (TV Ad26+ vs TV Ad26-) was used for analysis.
NS = not significant.